tbuckley/cabot-search huggingface dataset:
Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States
Authors: Scott V. Adams, Polly A. Newcomb, Andrei R. Shustov
Journal: Journal of Clinical Oncology (2016)

Purpose To compare incidence and survival of peripheral T-cell lymphoma (PTCL) subtypes among US racial/ethnic groups. Methods Patients with PTCL (age ≥ 15 years; 2000 to 2012) were identified in the Surveillance, Epidemiology, and End Results (SEER) registries. Race/ethnicity was categorized as non-Hispanic white, black, Asian/Pacific Islander, Hispanic white, or American Indian/Alaskan native. Age-standardized annual incidence rates and incidence rate ratios were estimated with 95% CIs, and case-case odds ratios were estimated by race/ethnicity using polytomous regression. Survival was estimated from SEER follow-up data with Cox regression. Results Thirteen thousand one hundred seven patients with PTCL were identified. Annual PTCL incidence was highest in blacks and lowest in Native Americans. Compared with non-Hispanic whites, blacks had a higher incidence of PTCL not otherwise specified (PTCL-NOS), anaplastic large-cell lymphoma, and adult T-cell leukemia/lymphoma (ATLL) and a lower incidence of angioimmunoblastic T-cell lymphoma (AITL); Asians/Pacific Islanders had a higher incidence of AITL, extranodal nasal-type natural killer/T-cell lymphoma and NK-cell leukemia (ENKCL), and ATLL and a lower incidence of anaplastic large-cell lymphoma; Hispanics had a higher incidence of AITL and ENKCL; and Native Americans had a lower incidence of PTCL-NOS (all P &lt; .05). The ratio of ENKCL to PCTL-NOS among Native Americans, Asians/Pacific Islanders, and Hispanic whites was approximately three- to four-fold the same ratio among non-Hispanic whites. Survival varied significantly by race/ethnicity (P &lt; .001), with blacks in particular experiencing shorter survival for most subtypes. Conclusion Striking variation in incidence, proportions of PTCL subtypes, and survival was observed. Aspects of these PTCL subtype patterns, such as for ENKCL and ATLL, were similar to corresponding global populations. Despite the small population size and limited number of Native American patients, PTCL subtype frequencies in this group were distinct but most similar to Hispanic whites. Survival disparities were evident, especially for blacks compared with non-Hispanic whites.
Alterations of surfactant phospholipids in lungs with chronic recurrent respiratory chlamydial infection
Authors: Petra Reinhold, Micheal Rothe
Journal: European Respiratory Journal (2011)

This study aimed to identify alterations in the composition of surfactant phospholipids (PLP) with respect to chronic respiratory chlamydial infection.

Broncho-alveolar lavage fluid (BALF) was sampled from 13 calves with naturally acquired chronic, but clinically latent, chlamydial infection ( C. pecorum and/or C. abortus ). Calves without chlamydial infections of the same age and kept under identical conditions served as controls (n = 12). Prior to BAL, exhaled breath condensate (EBC) was collected in each animal. In both BALF and EBC, phospholipids were measured (triplequad tandem mass spectrometer). Phosphatidylcholine (PC), being the main phospholipid in pulmonary surfactant and measurable in both EBC and in BALF samples, was significantly reduced in animals with chlamydial infections. In addition, concentrations of lysophosphatidylcholin, phosphatidylethanolamine (PE), and phosphatidylinositol (PI) were significantly reduced in BALF (not measurable in EBC). Altogether, total concentration of phospholipids was significantly lower but ratios between PC/PI and PG/PE (PG: phosphatidylglycerol) were significantly higher in calves with chlamydial infection compared to controls.

In conclusion, chronic respiratory infections with chlamydiae were associated with significant alterations in the phospholipid composition of the epithelial lining fluid of the lung. Since surfactant is involved in both lung compliance as well as alveolar clearance, results of this study indicate chlamydia-associated deterioration of pulmonary mechanics and depressed alveolar defense mechanisms despite the absence of clinical signs or pulmonary symptoms.
급성 A형간염 이환기간 중 발생한 횡문근융해증 1예
Authors: 안서희, 안건희, 이수연, 옥주현, 문형일, 문설경, 이영석, 한남익
Journal: Clinical and Molecular Hepatology (2009)

발열, 전신 근육통을 주소로 내원하여 시행한 혈청검사에서 급성 A형간염으로 진단된 환자에서 A형간염 이환기간 중 횡문근융해증이 발생하여 수액요법 및 보존적인 치료로 호전된 사례 1예를 경험하였기에 문헌고찰과 함께 보고한다.
An open letter to<i>The BMJ</i>editors on qualitative research
Authors: Trisha Greenhalgh, Ellen Annandale, Richard Ashcroft, James Barlow, Nick Black, Alan Bleakley, Ruth Boaden, Jeffrey Braithwaite, Nicky Britten, Franco Carnevale, Kath Checkland, Julianne Cheek, Alex Clark, Simon Cohn, Jack Coulehan, Benjamin Crabtree, Steven Cummins, Frank Davidoff, Huw Davies, Robert Dingwall, Mary Dixon-Woods, Glyn Elwyn, Eivind Engebretsen, Ewan Ferlie, Naomi Fulop, John Gabbay, Marie-Pierre Gagnon, Dariusz Galasinski, Ruth Garside, Lucy Gilson, Peter Griffiths, Penny Hawe, Jan-Kees Helderman, Brian Hodges, David Hunter, Margaret Kearney, Celia Kitzinger, Jenny Kitzinger, Ayelet Kuper, Saville Kushner, Andree Le May, France Legare, Lorelei Lingard, Louise Locock, Jill Maben, Mary Ellen Macdonald, Frances Mair, Russell Mannion, Martin Marshall, Carl May, Nicholas Mays, Lorna McKee, Marissa Miraldo, David Morgan, Janice Morse, Sarah Nettleton, Sandy Oliver, Warrren Pearce, Pierre Pluye, Catherine Pope, Glenn Robert, Celia Roberts, Stefania Rodella, Jo Rycroft-Malone, Margarete Sandelowski, Paul Shekelle, Fiona Stevenson, Sharon Straus, Deborah Swinglehurst, Sally Thorne, Göran Tomson, Gerd Westert, Sue Wilkinson, Brian Williams, Terry Young, Sue Ziebland
Journal: BMJ (2016)

Seventy six senior academics from 11 countries invite <i>The BMJ</i>'s editors to reconsider their policy of rejecting qualitative research on the grounds of low priority. They challenge the journal to develop a proactive, scholarly, and pluralist approach to research that aligns with its stated mission
Outcomes differences for African Americans and Caucasians treated with bevacizumab, FOLFOX4 or the combination in patients with metastatic colorectal cancer (MCRC): Results from the Eastern Cooperative Oncology Group Study E3200
Authors: P. J. Catalano, E. P. Mitchell, B. J. Giantonio, N. J. Meropol, A. B. Benson
Journal: Journal of Clinical Oncology (2007)

4100 Background: The relationship between race and clinical outcomes with systemic chemotherapy in patients with metastatic colorectal cancer is uncertain. E3200 is a large, randomized, multicenter phase III trial that demonstrated a gain in overall survival (OS), progression free survival (PFS) and response (RR) for the addition of bevacizumab to FOLFOX4 in previously treated patients with MCRC. We analyzed outcomes for African Americans and Caucasian patients enrolled in E3200. Methods: Patients enrolled in E3200 were randomized to one of three treatments: FOLFOX4, bevacizumab, or the combination. OS, PFS, RR and cycles of chemotherapy were examined as a function of race in 779 patients. Demographic information including race was collected by data management personnel at study sites and reported at registration. Results: There were no differences noted for Caucasians and African Americans with regards to: disease extent, performance status, gender, prior therapy and age distribution (not shown). Outcomes by race are tabulated. Conclusion: These results suggest outcomes differences based on race in the treatment of patients with MCRC. Additional studies are required to elucidate the cause for the observed variation. [Table: see text] No significant financial relationships to disclose.
β-Giucosidase Modulation in Preweanling Rats and Its Association With Tumor Induction by Cycasin&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN2"&gt;3&lt;/xref&gt;
Authors: H Matsumoto, Y Nagata, E T Nishimura, R Bristol, M Haber
Journal: JNCI Journal of the National Cancer Institute (1972)
A xenogeneic PSMA DNA vaccine for patients (pts) with non-castrate metastatic (NCMPC) and castrate metastatic prostate cancer (CMPC)—A phase I trial of proof of principle
Authors: S. Slovin, P. Gregor, J. Wolchok, A. Pedraza, F. Orlandi, M. Jefferson, M. Jefferson, C. Fernandez, J. Rudolph, A. Houghton, H. Scher
Journal: Journal of Clinical Oncology (2007)

3073 Background: Prostate Specific Membrane Antigen (PSMA) represents a target for both primary and metastatic prostate cancer and an anti-angiogenic approach for other solid tumors. Antitumor effects in PC have been observed using autologous dendritic cells pulsed with PSMA peptides. This is a pilot phase I trial of vaccination with a DNA encoding PSMA in patients with PC. The objective was to determine the safety and immunogenicity of vaccination with the genes encoding for mouse and human PSMA in patients with recurrent disease. The hypothesis was that xenogeneic DNA encoding a xenogeneic homologous antigen was a more potent immunogen than self DNA. Methods: Thirty-six HLA-A0201 + pts with either NCMPC or CMPC were randomly assigned to vaccination with either xenogeneic (mouse) or human (self) PSMA DNA delivered i.m. via a high pressure delivery system at 100μg, 1,500μg or 4,000μg every 3 weeks for 3 immunizations. Those pts randomized initially to receive human PSMA DNA received 3 immunizations with mouse PSMA DNA at three week intervals. Sera and peripheral blood mononuclear cells were analyzed for humoral and T cell responses Results: Twenty-nine of 36 pts were evaluable having received all six vaccines. Nine remain active without disease progression or significant change in PSA logslope. One of 6 pts treated at the 4,000μg cohort has been followed by &gt; 92 weeks; at the 1,500μg cohort 1 of 2 pt has been monitored for &gt; 110 weeks; and 1 pt at the 100μg dose has remained on study for &gt; 169 weeks. No high titer antibodies against PSMA were detected by ELISA or FACS against 3T3 fibroblasts transduced to express PSMA. Conclusions: The vaccine was safe at all dose levels without evidence of autoimmune reactivity. While antibodies against PSMA were not detected, studies are ongoing to examine T cell responsiveness. The majority of pts who remain on study were treated at 4,000μg dose level which appears to be the optimal dose. Supported by The Prostate Cancer Foundation and MSKCC Prostate Cancer SPORE No significant financial relationships to disclose.
Use of tumor arterial perfusion assessment and RECIST for prediction of survival and residual disease in hepatocellular carcinoma following intra-arterial infusion chemotherapy.
Authors: J. R. Daniels, M. A. Wallman, J. A. Donovan, A. B. El-Khoueiry, S. Iqbal, M. Hart, J. Pena
Journal: Journal of Clinical Oncology (2010)

4128 Background: Tumor responses of hepatocellular carcinoma (HCC) are usually classified by RECIST criteria. Residual tumor perfusion indicated by arterial phase contrast enhancement may provide additional information regarding tumor viability. We evaluated HCC responses using both RECIST and residual arterial phase contrast tumor perfusion for contributions toward prediction of survival after treatment in nontransplant patients and for likelihood of residual disease in explants. Methods: This is a retrospective analysis. Pre- and post-treatment tumor sizes and post- treatment contrast enhancement characteristics were determined by multiphase CT or MR at 0, 30, 70, and 180 seconds after contrast injection. Post-treatment scans were performed 6 weeks after last IA. Nonperfusion (NP) was defined by absence of enhancement in residual tumor. For pts not undergoing transplant survival hazard rates were estimated for multiple baseline and treatment variables using uni- and multivariate analysis. For transplanted pts, liver explants were examined for residual viable tumor. Results: 189 pts with nonmetastatic HCC were treated with intra-arterial cisplatin and mitomycin, 35 receiving salvage adriamycin and 24 percutaneous ablation. Transplant: 53 of 189 pts underwent liver transplantation. Of 27 patients achieving NP status, 12 (44.4%) had no residual disease vs. 2 of 23 patients (8.7%) with residual enhancement had no residual disease. Nontransplant: 136 patients have been followed without transplant. Multivariate analyses demonstrated predictive significance (p<0.001) for survival for RECIST response, NP status, number of treatments, and treatment toxicity. At 3 yrs, no patient with residual perfusion was alive vs. 10/55 (18.2%) patients achieving NP status. Conclusions: Response most strongly correlates with residual disease in explants and survival in nontransplanted patients considering both RECIST and perfusion status after treatment. Survival 1-year 3-year N % N % N 3-yr CR 16 11.8 14 93.8 6 84.4 PR- NP 27 19.9 13 78.3 3 40.1 PR-P 18 13.2 10 59.2 0 0 SD-NP 12 8.8 6 73.3 1 18.3 SD-P 44 32.2 11 30.6 0 0 PD 19 13.9 5 24.5 0 0 No significant financial relationships to disclose.
Environment Impacts the Metabolic Dependencies of Ras-Driven Non-Small Cell Lung Cancer
Authors: Shawn M. Davidson, Thales Papagiannakopoulos, Benjamin A. Olenchock, Julia E. Heyman, Mark A. Keibler, Alba Luengo, Matthew R. Bauer, Abhishek K. Jha, James P. O’Brien, Kerry A. Pierce, Dan Y. Gui, Lucas B. Sullivan, Thomas M. Wasylenko, Lakshmipriya Subbaraj, Christopher R. Chin, Gregory Stephanopolous, Bryan T. Mott, Tyler Jacks, Clary B. Clish, Matthew G. Vander Heiden
Journal: Cell Metabolism (2016)
Ischaemic heart disease in women: are there sex differences in pathophysiology and risk factors?: Position Paper from the Working Group on Coronary Pathophysiology and Microcirculation of the European Society of Cardiology
Authors: V. Vaccarino, L. Badimon, R. Corti, C. de Wit, M. Dorobantu, A. Hall, A. Koller, M. Marzilli, A. Pries, R. Bugiardini
Journal: Cardiovascular Research (2010)

Cardiovascular disease (CVD) is the leading cause of death in women, and knowledge of the clinical consequences of atherosclerosis and CVD in women has grown tremendously over the past 20 years. Research efforts have increased and many reports on various aspects of ischaemic heart disease (IHD) in women have been published highlighting sex differences in pathophysiology, presentation, and treatment of IHD. Data, however, remain limited. A description of the state of the science, with recognition of the shortcomings of current data, is necessary to guide future research and move the field forward. In this report, we identify gaps in existing literature and make recommendations for future research. Women largely share similar cardiovascular risk factors for IHD with men; however, women with suspected or confirmed IHD have less coronary atherosclerosis than men, even though they are older and have more cardiovascular risk factors than men. Coronary endothelial dysfunction and microvascular disease have been proposed as important determinants in the aetiology and prognosis of IHD in women, but research is limited on whether sex differences in these mechanisms truly exist. Differences in the epidemiology of IHD between women and men remain largely unexplained, as we are still unable to explain why women are protected towards IHD until older age compared with men. Eventually, a better understanding of these processes and mechanisms may improve the prevention and the clinical management of IHD in women.
A biomarker panel associated with distant metastasis in prostate cancer patients treated with radiotherapy as prognostic for DM in a large cohort of prostatectomy patients.
Authors: Alan Pollack, Nicholas Erho, Roshan Noronha, Lucia L.C. Lam, Christine Buerki, Sakhi Abraham, Eric A. Klein, R. Jeffrey Karnes, Robert Benjamin Den, Adam Dicker, Adrian Ishkanian, Elai Davicioni, Felix Yi-Chung Feng, Radka Stoyanova
Journal: Journal of Clinical Oncology (2015)

8 Background: A number of biomarkers related to cell cycle, angiogenesis or apoptosis have been found to be associated with patient outcome in tissue samples from men treated with first line radiation therapy in RTOG clinical trials using immunohistochemical staining and analysis. In a prior study, four biomarkers (Ki-67, MDM2, p16 and Cox-2) and clinical covariates were included in a model of distant metastasis (DM; Pollack et al, Clin Cancer Res, 2014 [epub ahead of print]) risk. The current study tested the hypothesis that these genes are prognostic for DM in men treated primarily with total prostatectomy using RNA expression profiling. Methods: RNA fromprostatectomy samples from Cleveland Clinic (CC, n=182); Mayo Clinic (MC)-I (n = 545) and II (n=235); Memorial Sloan Kettering Cancer Center (MSKCC, n=131); Erasmus Medical Center (EMC, n=48) and Thomas Jefferson University (TJU, n=130) were profiled using 1.4 million RNA features. A Cox proportional hazards model was built on the MC-I training set to combine the 4 biomarkers into a prognostic risk score (4BMSig). 4BMSig was subsequently evaluated for its prognostic significance separately and in combination with clinical risk factors (biopsy Gleason Score, cT-category and Preop-PSA) for DM. Results: 4BMSig was found to discriminate DM patients significantly for the MC-II (AUC = 0.66, p &lt; 0.001), CCF (AUC = 0.68, p &lt; 0.001), and MSKCC (AUC = 0.71, p = 0.04) datasets, and achieved borderline significance for EMC (AUC = 0.70, p = 0.06). 4BMSig did not discriminate DM in the TJU dataset (only 10 DM events). Pooled multivariable analysis (n = 726) with clinical covariates revealed that 4BMSig is a strong independent prognostic covariate for DM (p &lt; 0.001) and prostate cancer specific mortality (p = 0.005). Conclusions: The four genes identified previously as being associated with DM in radiotherapy patients were incorporated herein into 4BMSig, which was found to have potential as a pretreatment prognostic DM risk assessment tool for men treated with prostatectomy. Further validation would consist of testing 4BMSig from RNA in diagnostic tissue from prostate cancer patients prior to prostatectomy.
Docetaxel (D) plus prednisone (P) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line chemotherapy in metastatic hormone refractory prostate cancer (HRPC): Phase II clinical trial with pharmacodynamic evaluation
Authors: A. Fontana, G. Bocci, M. D’Arcangelo, L. Galli, C. Galli, S. Bursi, L. Landi, A. Antonuzzo, M. Del Tacca, A. Falcone
Journal: Journal of Clinical Oncology (2008)

16084 Background: Docetaxel based chemotherapy has became the standard of care for metastatic HRPC, moreover, low-dose metronomic antiangiogenic CTX and C have demonstrated a significant activity in preclinical and clinical studies without relevant toxicities. Combination of such strategies could be of interest in prostate cancer patients. Methods: A total of 19 patients with metastatic HRPC received D 60 mg/sqm iv day 1 every 3 weeks up to 12 cycles and from day 2 in a continuous fashion: P 5 mg po BID, CTX 50 mg po daily and C 200 mg po BID. Primary end point was PFS; secondary were: activity (PSA reduction >50%); objective responses, toxicities (NCI-CTC criteria), OS, evaluation of plasma levels of thrombospondin-1 (TSP-1), VEGF, sVEGFR-2, VE-cadherin mRNA; expression and synthesis of TSP-1 and VEGF in peripheral blood mononuclear cells. Patients (pts) characteristics: median age 69,5 years (59–78), median PS 1 (0–2), median baseline PSA 48,3 ng/ml (10–444); main sites of disease: bone 17 pts (90%), lymphnodes 1 pt (5%), liver 1 pt (5%). Results: 14 pts were evaluable for toxicity and response. Median number of docetaxel cycles administered was 8,5 (1–12) and median duration of metronomic CTX plus P and C was 183 days (18–636 days). Overall PSA decrease ≥ 50% was found in 11 pts (78%), with 6 patients that achieved a PSA complete response (43%). Three pts showed stable disease (21%). Up today, only 4 pts (28%) experienced disease progression. Median time to PSA progression was 7,7 months (3,7–10,3 months). Main grade 3 hematologic or non-hematologic toxicities were: neutropenia (1 pt; 5%) and diarrhoea (1 pt, 5%). No grade 4 toxicities have been observed. Conclusions: combination of docetaxel plus metronomic chemotherapy with CTX and C was feasible and showed only mild toxicity, preliminary activity was also interesting. The evaluation of biologic and pharmacodynamic effects of the combination is ongoing. No significant financial relationships to disclose.
Results of a clinical trial in humans with refractory cancer of the intracellular histamine antagonist, N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine-HCl, in combination with various single antineoplastic agents.
Authors: L J Brandes, K J Simons, S P Bracken, R C Warrington
Journal: Journal of Clinical Oncology (1994)

PURPOSE We assessed N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine-HCl (DPPE) potentiation of chemotherapy in vitro and performed a pharmacokinetic study and phase I/II trial of DPPE, combined with various single agents, in patients with advanced refractory cancer. PATIENTS AND METHODS In vitro chemopotentiation by DPPE was assessed in drug-sensitive and -resistant (multidrug resistant-positive [MDR+]) human tumor cells using a colony survival assay. The effect of DPPE and verapamil on the intracellular concentration of daunorubicin in MDR+ cells was compared. For the clinical study, subjects with progressive malignancy received a weekly infusion of a maximally tolerated dose of DPPE (240 mg/m2) over 80 or 440 minutes, in conjunction with a single chemotherapy drug to which, in most cases, the patient's tumor was previously resistant. Concentrations of DPPE in blood and urine were determined by high-performance liquid chromatography (HPLC). RESULTS In vitro, micromolar concentrations of DPPE potentiated (fivefold to 10-fold) chemotherapy cytotoxicity to both drug-sensitive and -resistant cells, but did not inhibit the p-glycoprotein pump; in vivo, serum levels of DPPE were 3 to 5 mumol/L at the end of 80 minutes and 1 to 2 mumol/L after 440 minutes of infusion. Of 48 patients monitored for a minimum of four DPPE/chemotherapy treatment cycles, 16 (33%) progressed, 12 (25%) stabilized, 12 (25%) improved, and eight (17%) responded (one complete and seven partial remissions). Four of 11 subjects who did not respond to the 80-minute infusion regimen improved with the 440-minute infusion; one had a partial remission of melanoma. In more than 600 patient-treatments, bone marrow toxicity was negligible (mean absolute neutrophil count [ANC] &gt; 2.0 x 10(9)/L). Acute CNS symptoms associated with DPPE infusions were of relatively short duration (1 to 4 hours); delayed toxicity attributable to DPPE consisted of mild nausea and/or fatigue (1 to 2 days). CONCLUSION Although preliminary, the results suggest that more structured trials should be performed to determine whether DPPE may increase the therapeutic index of certain chemotherapy drugs.